All In Biotech

Drug Trial Radar · NCT02876835

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,872 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,872

Actual

Start

Sep 27, 2016

Primary completion

Apr 19, 2021

Study completion Apr 19, 2021

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

Conditions

  • Anaemia

Interventions

  • DaprodustatDrug

    The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.

  • Darbepoetin alfaDrug

    The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.

  • PlaceboDrug

    Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

  • Iron TherapyDrug

    Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)Time frame: Up to 4.3 person-years for CV follow-up time period
  2. Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Locations

574 sites in 39 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Andalusia, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Azusa, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    Cudahy, California

  • GSK Investigational Site

    El Centro, California

  • GSK Investigational Site

    Escondido, California

  • GSK Investigational Site

    Glendale, California

  • GSK Investigational Site

    Granada Hills, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    La Palma, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Montebello, California

  • GSK Investigational Site

    National City, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Luis Obispo, California

  • GSK Investigational Site

    Simi Valley, California

  • GSK Investigational Site

    Tarzana, California

  • GSK Investigational Site

    Whittier, California

  • GSK Investigational Site

    Middlebury, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Cutler Bay, Florida

  • GSK Investigational Site

    Doral, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

Showing 40 of 574 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.